Results 251 to 260 of about 1,915,609 (322)
Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles
Molecular Oncology, EarlyView.Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea +9 morewiley +1 more sourceDetecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data
Molecular Oncology, EarlyView.This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda +12 morewiley +1 more sourceP409: Clinical utility of genomic sequencing for hereditary cancer syndromes: An observational chart review
Genetics in Medicine Open, 2023 Salma Shickh, Chloe Mighton, Marc Clausen, Rita Kodida, Jordan Sam, Daena Hirjikaka, Emma Reble, Tracy Graham, Seema Panchal, Andrea Eisen, Christine Elser, Kasmintan Schrader, Nancy N. Baxter, Andreas Laupacis, Jordan Lerner-Ellis, Raymond Kim, Yvonne Bombard +16 moredoaj Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey
Molecular Oncology, EarlyView.This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin +6 morewiley +1 more sourceLandscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno +5 morewiley +1 more sourceP516: The Genetics Navigator: The development and usability testing of a new patient-facing digital health application to support clinical genetic testing
Genetics in Medicine OpenMarc Clausen, Stephanie Luca, Emma Reble, Rita Kodida, Saumeh Saeedi, Daena Hirjikaka, Lauren Chad, Gregory Costain, Hanna Faghfoury, Josh Silver, Serena Shastri-Estrada, Maureen Smith, Robin Hayeems, Yvonne Bombard +13 moredoaj
